The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis

Niranjan J. Sathianathen, Mohit Butaney, Badrinath R. Konety

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Introduction: Conventional imaging modalities have been poor in characterizing the true extent of disease in men with biochemical recurrence following primary treatment for prostate cancer. Functional imaging with positron emission tomography (PET) has shown promise of being a superior imaging modality. We conducted a systematic review and meta-analysis to define the diagnostic accuracy of PET/CT using 11C-choline, 18F-FACBC, or 68Ga-PSMA in detecting recurrent prostate cancer. Methods: We searched multiple databases in line with the preferred reporting items for systematic review and meta-analysis (PRISMA) statement to define the diagnostic accuracy of 11C-choline, 18F-FACBC, or 68Ga-PSMA PET/CT. Only studies secondarily staging participants with biochemical recurrence and those with an appropriate reference standard (pathology, further imaging, and/or clinical response) were eligible for analysis. Results: Twenty-one studies with 3202 participants met the inclusion criteria. Of these, 11C-choline, 18F-FACBC, and 68Ga-PSMA were the tracer investigated in 16, 5, and 1 studies, respectively. The summary sensitivity for each tracer was 80.9% (95% CI 70.4–88.3%), 79.7% (95% CI 51.9–93.4%), and 76.4% (95% CI 68.3–82.9%), respectively. The corresponding summary specificity was 84.1% (95% CI 70.2–92.2%), 61.9% (95% CI 41.1–79.0%), and 99.8% (95% CI 97.5–100%), respectively. Detection rates ranged between 58.6 and 82.8%. All included studies were judged to be at high risk of bias primarily due to study limitations pertaining to the reference standard. Conclusion: There is a lack of high-quality data to verify the accuracy of PET-based imaging using 11C-choline, 18F-FACBC, or 68Ga-PSMA. The early results are encouraging that these techniques are superior to conventional imaging modalities, which would allow salvage therapies to be optimized.

Original languageEnglish (US)
Pages (from-to)1239-1249
Number of pages11
JournalWorld Journal of Urology
Issue number7
StatePublished - Jul 1 2019

Bibliographical note

Funding Information:
Funding NJS has received support from the Cloverfields Foundation and The Institute for Prostate and Urologic Cancers (University of Minnesota).

Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.


  • Cancer staging
  • Positron emission tomography
  • Prostate cancer
  • Systematic review


Dive into the research topics of 'The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this